Want to see AKTX full AI Analyst Report?
AKTX Stock Chart & Stats
$7.87
-$0.24(-2.76%)
At close: 4:00 PM EDT
$7.87
-$0.24(-2.76%)
Day’s Range― - ―
52-Week Range$3.02 - $44.20
Previous Close$8.46
Volume52.72K
Average Volume (3M)78.89K
Market Cap
$15.47M
Enterprise Value$11.29
Total Cash (Recent Filing)$7.69M
Total Debt (Recent Filing)$693.00K
Price to Earnings (P/E)―
Beta1.47
Next Earnings
Apr 21, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1600.00
Shares Outstanding1,946,982
10 Day Avg. Volume67,220
30 Day Avg. Volume78,895
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00
P/FCF Ratio-0.02
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$25.50Price Target Upside224.02% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-10.67
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageVery limited debt reduces fixed financial obligations and interest-related pressure while Akari remains in development. This gives management more flexibility to allocate available capital toward research and clinical programs, although it does not eliminate the need for future funding.
Focused Therapeutic StrategyA defined focus on autoimmune and inflammatory diseases can help concentrate a small organization’s research resources around related biological pathways. That specialization may support clearer development priorities and a coherent long-term strategy as investigational candidates advance.
Equity-linked Management IncentivesLinking a meaningful portion of executive compensation to restricted stock and multi-year vesting can align management incentives with longer-term shareholder outcomes. The structure also creates formal shareholder oversight because key awards require approval under the equity plan.
Bears Say
No Revenue GenerationAkari remains pre-revenue, so its operations are not currently funded by product sales or recurring commercial demand. Until a candidate reaches commercialization, the company must rely on financing or other capital sources to sustain development and build future earning power.
Widening Net LossesThe sharp increase in net losses indicates deteriorating earnings power and a higher cost burden while revenue remains absent. Persistent losses can consume the capital base, reduce financial flexibility, and increase the amount of external funding required to continue clinical development.
Persistent Cash Burn And Dilution RiskNegative operating and free cash flow show that Akari is consuming cash rather than generating internally funded resources. Combined with declining equity, this raises the likelihood of additional external financing and potential shareholder dilution before revenue begins.
Akari Therapeutics News
AKTX FAQ
What was Akari Therapeutics’s price range in the past 12 months?
Akari Therapeutics lowest stock price was $3.02 and its highest was $44.20 in the past 12 months.
What is Akari Therapeutics’s market cap?
Akari Therapeutics’s market cap is $15.47M.
When is Akari Therapeutics’s upcoming earnings report date?
Akari Therapeutics’s upcoming earnings report date is Apr 21, 2027 which is in 199 days.
How were Akari Therapeutics’s earnings last quarter?
Akari Therapeutics released its earnings results on Aug 13, 2026. The company reported $0 earnings per share for the quarter, beating the consensus estimate of -$1.04 by $1.04.
Is Akari Therapeutics overvalued?
According to Wall Street analysts Akari Therapeutics’s price is currently Undervalued.
Does Akari Therapeutics pay dividends?
Akari Therapeutics does not currently pay dividends.
What is Akari Therapeutics’s EPS estimate?
Akari Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Akari Therapeutics have?
Akari Therapeutics has 1,946,982 shares outstanding.
What happened to Akari Therapeutics’s price movement after its last earnings report?
Akari Therapeutics reported an EPS of $0 in its last earnings report, beating expectations of -$1.04. Following the earnings report the stock price went up 7.714%.
Which hedge fund is a major shareholder of Akari Therapeutics?
Currently, no hedge funds are holding shares in AKTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Akari Therapeutics
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company’s lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others. Its payloads include PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Tampa, Florida.
AKTX Stock 12 Month Forecast
Average Price Target
$25.50
▲(224.02% Upside)
Technical Analysis
Ownership Overview
25.66% Insiders
7.32% Other Institutional Investors
67.02% Public Companies and
Individual Investors